China-US IPO Observation 2025
Special Topic Overview
In 2025, the window for Chinese companies to list in the US appears to show a glimmer of hope, but thunder lurks beneath.
As US-China trade tensions continue to escalate, four major barriers have been simultaneously activated: the CSRC filing system, CAC data security review, Nasdaq's $25 million threshold, and the SEC's cross-border fraud task force. The 159 existing companies using VIE structures (accounting for 91% of Chinese market cap in US stocks) are facing the strictest compliance and survival pressure in history.
Surface data still looks impressive: an estimated 35-40 Chinese companies are expected to ring the bell in the US this year, raising $1.5-1.8 billion; but in essence, this is the most brutal shakeout since the 2021 regulatory storm, with only companies possessing genuine hard-tech barriers and compliance capabilities able to cross this "life-or-death line."
Core Issues
From "Quantity Game" to "Quality Survival"
The biggest variables come from two new policies:
-
Nasdaq September 2025 Proposal (expected to take effect in Q1 2026):
- Minimum IPO fundraising of $25 million + public float of $15 million for Chinese companies
- 3 times the original threshold, expected to eliminate 40-50% of small-cap stocks
-
CSRC Filing System + CAC Data Security Review:
- Extended to 6-12 months
- VIE structure companies (currently 159 out of 286 in US stocks, accounting for 91% of market cap) face dual barriers
Industry Distribution
Autonomous driving, new energy, and AI infrastructure remain the hottest tracks, accounting for over 60% of listed/submitted companies.
Special Topic Chapters
This special topic releases four in-depth reports, analyzing the four most critical dimensions:
Chapter 1: 2025 China-US IPO List: 40 Submitted, Who Can Break Nasdaq's $25M Threshold?
The real list of 40 companies that have submitted S-1/F-1 and the brutal screening process
Core Content:
- Complete list of 40 companies and fundraising data
- Analysis of Nasdaq's $25 million threshold impact
- Industry distribution and growth rate comparison
- VIE risk assessment
Chapter 2: Life-or-Death Line for Chinese Medical Companies' US Listing: How SEC Targets LVAD Data Risks
Data transparency red lines and SEC audit minefields in the medical sector
Core Content:
- LVAD (Left Ventricular Assist Device) data disclosure requirements
- SEC's focus on medical data review
- Compliance challenges for Chinese medical companies
- Typical case analysis
Chapter 3: 2025 China Outbound IPO Industry Heatmap: AI and New Energy Lead
Fundraising scale, growth rate, and risk distribution of the AI and new energy dual engines
Core Content:
- AI company IPO trends and valuations
- New energy company fundraising scale
- Industry heatmap and risk distribution
- Investment opportunity analysis
Chapter 4: CSRC New Audit Policy: Escalating Difficulty for Chinese Companies' US IPOs
Approval period extended to 6-12 months, why Hong Kong dual listing becomes a safe haven
Core Content:
- CSRC new policy details
- Approval process and timeline extension
- Advantages of Hong Kong dual listing
- Alternative pathway analysis
Core Perspective
From Robotaxi to battery giants, from LiDAR to left ventricular assist devices, we not only present lists and numbers, but also dissect the dismantling costs behind each VIE, the data gaps behind each SEC supplemental letter, and the silent stories of those eliminated behind each $25 million threshold.
This is not a winter, but an evolution.
China's US IPOs in 2025 will completely shift from a "quantity game" to "quality survival."
Only companies and investors who understand the new rules and see the new red lines clearly can break through in this global capital examination.
This special topic is original content from GFM's "IPO Watch" column. All data comes from CSRC, SEC EDGAR, Nasdaq official disclosures, and frontline research.